BRIAN WINFIELD: Open Payments
NPI 1295827053 · NEWARK, DE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,964 in 86 payments from 20 companies in 2025. Trend: 2023 $0 · 2024 $869 · 2025 $1,964
Food & beverage: $1,964
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $474 |
| Phathom Pharmaceuticals, Inc. | 12 | $264 |
| GENZYME CORPORATION | 5 | $149 |
| Janssen Biotech, Inc. | 6 | $140 |
| Madrigal Pharmaceuticals | 5 | $137 |
| Ardelyx, Inc. | 6 | $134 |
| Lilly USA, LLC | 6 | $124 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $112 |
| Daiichi Sankyo Inc. | 3 | $60 |
| EVOKE PHARMA, INC. | 3 | $55 |
Products named: ENTYVIO, VOQUEZNA, DUPIXENT, TREMFYA, REZDIFFRA, IBSRELA, OMVOH, XIFAXAN.
Industry payments across DE — which companies pay providers there.
